Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Biological markers of Alzheimer's disease and mild cognitive impairment.

Maccioni RB, Lavados M, Maccioni CB, Mendoza-Naranjo A.

Curr Alzheimer Res. 2004 Nov;1(4):307-14. Review.

PMID:
15975059
2.

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

Sjögren M, Andreasen N, Blennow K.

Clin Chim Acta. 2003 Jun;332(1-2):1-10. Review.

PMID:
12763273
3.

Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.

Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.

Neurobiol Aging. 2006 Feb;27(2):237-44. Epub 2005 Apr 7.

PMID:
16399209
4.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
5.

Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.

Blennow K, Vanmechelen E.

J Neural Transm Suppl. 1998;53:223-35. Review.

PMID:
9700660
6.

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P.

Neurobiol Aging. 2006 Mar;27(3):394-401. Epub 2005 Aug 26.

PMID:
16125823
7.

Biomarkers of mild cognitive impairment and Alzheimer's disease.

Tang BL, Kumar R.

Ann Acad Med Singapore. 2008 May;37(5):406-10.

8.

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.

van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.

Neurology. 2009 Mar 24;72(12):1056-61. doi: 10.1212/01.wnl.0000345014.48839.71.

PMID:
19307538
9.

CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.

Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.

J Neurol Sci. 2006 Dec 21;251(1-2):124-8. Epub 2006 Nov 9.

PMID:
17097109
10.

Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.

Formichi P, Battisti C, Radi E, Federico A.

J Cell Physiol. 2006 Jul;208(1):39-46. Review.

PMID:
16447254
11.

Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings.

Hartmann AP, Almeida SM, Livramento JA, Nitrini R, Takahashi D, Caramelli P.

Arq Neuropsiquiatr. 2004 Sep;62(3B):751-5. Epub 2004 Oct 5.

12.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
13.

CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.

Fellgiebel A, Kojro E, Müller MJ, Scheurich A, Schmidt LG, Fahrenholz F.

J Geriatr Psychiatry Neurol. 2009 Mar;22(1):3-9. doi: 10.1177/0891988708327810. Epub 2008 Dec 10.

PMID:
19073834
14.

Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.

Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.

Neurodegener Dis. 2008;5(5):268-76. doi: 10.1159/000119457. Epub 2008 Feb 29.

PMID:
18309230
15.

Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.

Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):80-5. doi: 10.1007/s00406-008-0838-3. Epub 2008 Sep 19.

PMID:
18806919
16.

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.

Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271.

PMID:
19858456
17.

Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.

Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.

Mech Ageing Dev. 2006 Feb;127(2):129-32. Epub 2005 Nov 7.

PMID:
16274728
18.

The basis for disease-modifying treatments for Alzheimer's disease: the Sixth Annual Mild Cognitive Impairment Symposium.

Duara R, Barker W, Loewenstein D, Bain L.

Alzheimers Dement. 2009 Jan;5(1):66-74. doi: 10.1016/j.jalz.2008.10.006.

PMID:
19118811
19.

Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease?

Funke SA, Birkmann E, Willbold D.

Curr Alzheimer Res. 2009 Jun;6(3):285-9. Review.

PMID:
19519310
20.
Items per page

Supplemental Content

Write to the Help Desk